Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (12068)	7/23/1998 7:42:00 PM
From: VLAD	Respond to of 23519

Ed, I never made any statement as to when Vivus would be bought out. Another factor to evaluate stock price is the shares that have already been sold short. For example, using todays close of 7 7/8 and the last short interest numbers of 13.5 million you would do the following calculation to figure a minimal price which assumes that all shorts are allowed to cover at 7 7/8 which is not even realistic. Outstanding is 31.125 million Current market cap is 7 7/8 x 31.125 = 245.1 million Value of shares already sold short 7 7/8 x 13.5 million = 106.3 million Market cap based on shorts covering at 7 7/8 = 351.4 million Share price based on short positions being covered: 351,400,000/31,125,000 = $11.30/share Now this calculation is not realistic in terms of the shorts being all allowed to cover at 7 7/8. If the average short covering price ends up being a more realistic number like 12 then the calculated share price becomes $13.00. Do you still think it is crazy to pay $20.00/share for a stock with over 1/2 its float sold short?

To: Edderd who wrote (12068)	7/23/1998 10:24:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

Ed, One other point to make. Vivus is on the NASDAQ which equates to extreme volatility. Not too long ago back in April Vivus stock price went from 7 5/8 to 14 1/4 in three trading days. There was no fundamental changes in the company at this time. The only thing that made people pay $14.00 for a stock that could have been bought in the 7's 3 days earlier was some hot air that came out of the mouth of an analyst who recommended Vivus as a buy based on MUSE's safety profile compared to Viaga. The things mentioned by the analyst have not changed, in fact after 39 confirmed Viagra linked deaths it is even more evident that MUSE's safety profile gives it an edge over Viagra's safety problems.